Jackson Center, PA, December 23, 2020 – Halberd Corp. (OTC PINK: "HALB") research has produced a second monoclonal antibody (mAb) against the Covid-19 spike protein. Initial testing displays a stronger affinity for the SARS-CoV-2 antigen than Halberd’s initial antibody. Testing continues through the holidays on each antibody to establish potency and specificity (i.e., targets only ...
Jackson Center, PA, December 17, 2020 – Halberd Corp. (OTC PINK: "HALB") announced they are pursuing development of their latest extracorporeal treatment variation in the fight against COVID-19. Halberd’s provisional patent application, “Method For Treating And Curing Covid-19 Infection By Utilizing Radio Frequency Extracorporeally To Eradicate The Virus,” was filed last month. The procedure is ...
Jackson Center, PA, December 14, 2020 – Halberd Corporation (OTC PINK: "HALB") announced its proprietary, highly potent, neutralizing antibody against SARS-CoV-2, which demonstrated very strong receptor specificity and inhibition of SARS-CoV-2 replication. Halberd’s anti-Spike protein monoclonal antibody, recently filed with the United States Patent Office, underwent in vitro studies at Arizona State University (ASU). Based ...
Phoenix, December 10th, 2020 (Newsfile Corp.) -- The Stock Day Podcast welcomed Halberd Corporation (HALB) (“the Company”), a company with a patented extracorporeal treatment applicable to many hard-to-cure blood-borne and neurological diseases, including Covid-19, other viruses, and PTSD. President and CEO of the Company, William A. Hartman, joined Stock Day host Everett Jolly. Jolly began ...
Jackson Center, PA, December 7, 2020 – Halberd Corporation (OTC PINK: "HALB") announced the promising results of laboratory testing on their new patent pending SARS-COV-2 monoclonal antibody generated through their university research. The antibody testing to date has shown extremely potent action against the SARS-CoV-2 spike protein. Scientific details of the testing to date will ...
Jackson Center, PA, December 2, 2020 – Halberd Corp. (OTC PINK: "HALB") was recently included in a Momentum Observer article on Covid-19 along with big pharma companies Pfizer (PFE: NYSE), Moderna (MRNA: NASDAQ), BioNTech (BNTX: NASDAQ) and AstraZeneca (AZN: NASDAQ). The article featured Halberd's nasal spray currently under development that could be an effective alternative ...
Jackson Center, PA, December 1, 2020 – Halberd Corp. (OTC PINK: "HALB") announces the reorganization of its Scientific Advisory Board. The new Advisory Board will consist of two sub-boards: a multi-disciplined Scientific Advisory Board focused on biomedical issues and a Business Advisory Board focusing on business issues. The two boards will interface on a regular ...
Jackson Center, PA, November 25, 2020 – Halberd Corporation (OTC-PINK: "HALB") Chairman, President and CEO, William A. Hartman, was interviewed this week by host, Donald Baillargeon, on Money TV. Mr. Hartman recapped the company’s accomplishments, describing its most promising technologies and described the unique applications perceived, including a sneak peek at the future. Mr. Hartman ...
Jackson Center, PA, November 19, 2020 – Halberd Corp. (OTC PINK: "HALB") reported the filing of a provisional patent application on a variation of Halberd’s patented extracorporeal method to treat/eradicate Covid-19 from a patient’s blood. By using an extracorporeal (outside the body) treatment method, the patient is exposed to far fewer potential negative side effects ...
Jackson Center, PA, November 12, 2020 – Halberd Corporation (OTC PINK: "HALB") today disclosed information on their patent-pending fluorescent anti-Spike protein monoclonal antibodies against Covid-19 developed in conjunction with Dr. Qiang (Shawn) Chen of Arizona State University. The salient feature of Halberd’s new class of antibody is that it fluoresces in the presence of Covid-19 ...